Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists

Arun Chandramohan, Anthony W. Partridge(Quantitative BioSciences), Andrea Peier(Merck & Co., Inc., Rahway, NJ, USA (United States)), David P. Lane(University of Dundee), Charles W. Johannes(Singapore Institute for Clinical Sciences), Ruchia Duggal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tsz Ying Yuen(Agency for Science, Technology and Research), Pietro G. A. Aronica(Agency for Science, Technology and Research), Srinivasaraghavan Kannan(Agency for Science, Technology and Research), Chandra Verma(Agency for Science, Technology and Research), Hubert Josien(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yee Hwee Lim(Agency for Science, Technology and Research), Jerome Hochman(United States Military Academy), Marika Nestor(Uppsala University), R. M. Garbaccio(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lin Yan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hung Yi Kristal Kaan, Christopher J. Brown(Institute of Molecular and Cell Biology), Lan Ge(Merck & Co., Inc., Rahway, NJ, USA (United States)), Songnian Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brian Henry(MSD K.K. (Japan)), Yu‐Chi Juang(Mount Sinai Hospital), Brad Sherborne(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kaustav Biswas(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tomi K. Sawyer(Merck & Co., Inc., Rahway, NJ, USA (United States)), Diana Spiegelberg(Uppsala University)
Nature Communications
January 12, 2024
Cited by 40


Related Papers